Skip to content
Inciteful Med

Introduction to Angelman Syndrome: What It Is and What to Expect First

Last updated:

Angelman syndrome is a rare genetic neurodevelopmental disorder caused by a missing or inactive UBE3A gene. While it causes developmental delays, non-verbal communication, and seizures, individuals with the condition generally have a normal life expectancy and a characteristically happy demeanor.

Key Takeaways

  • • Angelman syndrome is a genetic neurodevelopmental disorder primarily caused by the loss of function of the maternal UBE3A gene.
  • • The condition is typically a random genetic event and is not caused by anything that occurred during pregnancy.
  • • While individuals with Angelman syndrome require lifelong care, they generally have a normal life expectancy.
  • • Common symptoms include a happy demeanor, developmental delays, lack of verbal speech, ataxia, and seizures.
  • • Experimental therapies like Antisense Oligonucleotides (ASOs) are currently in clinical trials and offer hope for future targeted treatments.

Receiving a diagnosis of Angelman syndrome (AS) can feel like a tidal wave of information and emotion. You may be hearing terms like “severe intellectual disability” and “genetic deletion” for the first time, which can be incredibly overwhelming [1]. It is important to know that while AS is a significant life-long condition, your child’s diagnosis is a roadmap, not a barrier to a joyful and meaningful life.

What is Angelman Syndrome?

Angelman syndrome is a neurodevelopmental disorder, a condition that affects how the brain develops and processes information [2]. It occurs in approximately 1 in 15,000 to 1 in 30,000 live births [3].

The primary biological cause of AS is the loss of function of a specific gene called UBE3A, located on the 15th chromosome [4]. In a typical brain, only the copy of this gene inherited from the mother is active in neurons; the father’s copy is “silenced.” In children with AS, the mother’s copy is missing or not working correctly, leaving the brain without the UBE3A protein it needs to manage how other proteins are broken down and recycled [5][6].

Foundational Facts for New Families

In the early days of a diagnosis, focusing on these stabilizing facts can help anchor your family:

  • It is not your fault: Angelman syndrome is almost always a random genetic event. It was not caused by anything you did or did not do during pregnancy or birth [4].
  • Life expectancy is generally normal: While people with AS require lifelong care, they generally have a normal lifespan [3].
  • There is a clear diagnostic path: AS is confirmed through specialized genetic tests (such as DNA methylation or UBE3A sequencing). Furthermore, an EEG (electroencephalogram) often shows a very specific “slow wave” pattern that can help doctors strongly suspect the diagnosis even before genetic results are finalized [7][8].
  • The “Happy” Demeanor: One of the most distinctive features of AS is a frequently happy, sociable personality with easily triggered laughter [2][9]. While this is a medical symptom, it often becomes a cherished part of a child’s unique personality.

What to Expect: The Early Years

Angelman syndrome affects several areas of development, and knowing what to expect can help you prepare for the road ahead:

  • Developmental Delays: You may notice your child reaching milestones like sitting or walking later than peers [4].
  • Communication: Most individuals with AS do not develop verbal speech, but they are often very effective “non-verbal” communicators, using gestures, signs, or technology to express themselves [10][11].
  • Motor Skills: Children often have ataxia, which refers to balance and coordination issues that can make their movements appear jerky or “stiff” [2][12].
  • Seizures and Sleep: About 85-90% of children will develop epilepsy, often by age three [13][14]. Sleep disturbances, including a significantly decreased need for sleep, are also very common [15][16].

Safety and Long-Term Health

While life expectancy is generally normal, families must stay vigilant regarding specific risks. The primary causes of mortality in the AS community are respiratory illnesses and accidents [3]. Due to a combination of ataxia, intellectual disability, and a common fascination with water, children with AS are at a high risk for wandering (elopement) and drowning. SUDEP (Sudden Unexpected Death in Epilepsy) is also a rare but recognized risk for those with poorly controlled seizures [3][17]. Regular follow-ups with a neurologist and safety-proofing your home (including strict water safety protocols) are essential steps in long-term management [18].

A Reason for Hope: Research Horizons

The landscape for Angelman syndrome is changing rapidly. Researchers are currently investigating Antisense Oligonucleotides (ASOs) [5]. This experimental therapy aims to “unsilence” the paternal (father’s) copy of the UBE3A gene that is already present in the brain [6][19]. While these therapies are still in early-to-mid-phase clinical trials and commercial availability is likely years away, they offer genuine hope for targeted, disease-modifying treatments in the future [20][21].

Frequently Asked Questions

What causes Angelman syndrome?
Angelman syndrome is primarily caused by a missing or malfunctioning UBE3A gene on the 15th chromosome. In almost all cases, this is a random genetic event rather than something inherited from the parents.
What is the life expectancy for someone with Angelman syndrome?
Individuals with Angelman syndrome generally have a normal lifespan. However, they do require lifelong care and supervision due to developmental delays, seizure risks, and a high risk of accidents like wandering.
How is Angelman syndrome diagnosed?
The diagnosis is typically confirmed through specialized genetic tests like DNA methylation or UBE3A sequencing. Doctors may also use an EEG, which often shows a specific slow wave pattern that strongly suggests the condition.
Will my child with Angelman syndrome be able to talk?
Most individuals with Angelman syndrome do not develop spoken language. However, they are often excellent non-verbal communicators who can express themselves effectively using gestures, sign language, or assistive communication technology.
What are the most common health and safety risks?
Up to 90% of children with the condition will develop epilepsy, usually by age three. Other major health and safety risks include severe sleep disturbances, balance issues (ataxia), and accidents related to a fascination with water and wandering.

Questions for Your Doctor

  • • What is the specific genetic mechanism causing my child's diagnosis (e.g., maternal deletion, UBE3A mutation, or paternal UPD)?
  • • Has my child's EEG shown the characteristic 'delta wave' pattern, and what does that mean for their seizure risk?
  • • Are there specific specialists, such as a neurogeneticist or a complex care pediatrician, you recommend for our care team?
  • • What is my child's current risk for seizures, and what signs should I be looking for at home?
  • • Can you explain the current landscape of clinical trials for ASO therapies and if my child might be a candidate in the future?

Questions for You

  • • What were the first signs or developmental delays that led us to seek an evaluation?
  • • How am I feeling about this diagnosis, and what kind of emotional or logistical support do I need right now?
  • • What are my primary goals for my child’s quality of life over the next year?
  • • Have I noticed any specific triggers for my child's 'happy' demeanor or any patterns in their sleep and wake cycles?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Caregiving Burden and Quality of Life Among Parents of Individuals With Angelman Syndrome: Gender Differences and the Impact of Financial Well-Being.

    Walkowiak D, Domaradzki J

    Pediatric neurology 2025; (169()):31-39 doi:10.1016/j.pediatrneurol.2025.05.005.

    PMID: 40449417
  2. 2

    Atypical presentation of Angelman syndrome with intact expressive language due to low-level mosaicism.

    Punatar R, Egense A, Mao R, et al.

    Molecular genetics & genomic medicine 2022; (10(10)):e2018 doi:10.1002/mgg3.2018.

    PMID: 35929060
  3. 3

    Community-Sourced Reporting of Mortalities in Angelman Syndrome (1979-2022).

    Gomes AT, Moore A, Cross M, et al.

    American journal of medical genetics. Part A 2025; (197(4)):e63961 doi:10.1002/ajmg.a.63961.

    PMID: 39679858
  4. 4

    Angelman syndrome - insights into a rare neurogenetic disorder.

    Buiting K, Williams C, Horsthemke B

    Nature reviews. Neurology 2016; (12(10)):584-93 doi:10.1038/nrneurol.2016.133.

    PMID: 27615419
  5. 5

    Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeys.

    Jagasia R, Bon C, Rasmussen SV, et al.

    Nucleic acids research 2025; (53(16)) doi:10.1093/nar/gkaf851.

    PMID: 40884397
  6. 6

    An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript.

    Dindot SV, Christian S, Murphy WJ, et al.

    Science translational medicine 2023; (15(688)):eabf4077 doi:10.1126/scitranslmed.abf4077.

    PMID: 36947593
  7. 7

    Genetic testing for Prader-Willi syndrome and Angelman syndrome in the clinical practice of Guangdong Province, China.

    Liu C, Zhang X, Wang J, et al.

    Molecular cytogenetics 2019; (12()):7 doi:10.1186/s13039-019-0420-x.

    PMID: 30820248
  8. 8

    Evaluation of electroencephalography biomarkers for Angelman syndrome during overnight sleep.

    Levin Y, Hosamane NS, McNair TE, et al.

    Autism research : official journal of the International Society for Autism Research 2022; (15(6)):1031-1042 doi:10.1002/aur.2709.

    PMID: 35304979
  9. 9

    Genotype-Phenotype Correlations in Angelman Syndrome.

    Yang L, Shu X, Mao S, et al.

    Genes 2021; (12(7)) doi:10.3390/genes12070987.

    PMID: 34203304
  10. 10

    Communication in Angelman syndrome: a scoping review.

    Pearson E, Wilde L, Heald M, et al.

    Developmental medicine and child neurology 2019; (61(11)):1266-1274 doi:10.1111/dmcn.14257.

    PMID: 31074506
  11. 11

    Atypical Angelman syndrome due to a mosaic imprinting defect: Case reports and review of the literature.

    Le Fevre A, Beygo J, Silveira C, et al.

    American journal of medical genetics. Part A 2017; (173(3)):753-757 doi:10.1002/ajmg.a.38072.

    PMID: 28211971
  12. 12

    Impact of Deletion on Angelman Syndrome Phenotype Variability: Phenotype-Genotype Correlation in 97 Patients with Motor Developmental Delay.

    Belghiti HD, Abbassi M, Sayel H, et al.

    Journal of pediatric genetics 2024; (13(1)):15-21 doi:10.1055/s-0042-1751268.

    PMID: 38567176
  13. 13

    [Epilepsy in Angelman syndrome and the most common electroencephalographic findings].

    Ebrat-Mancilla E, Sánchez-Aparicio A, Pérez de Vargas-Martínez A, et al.

    Revista de neurologia 2024; (79(8)):223-228 doi:10.33588/rn.7908.2024233.

    PMID: 39404036
  14. 14

    Angelman syndrome presenting with a rare seizure type in a patient with 15q11.2 deletion: a case report.

    Ranasinghe JC, Chandradasa D, Fernando S, et al.

    Journal of medical case reports 2015; (9()):142 doi:10.1186/s13256-015-0622-8.

    PMID: 26077608
  15. 15

    Sleep in children with Angelman syndrome: Parental concerns and priorities.

    Trickett J, Heald M, Oliver C

    Research in developmental disabilities 2017; (69()):105-115 doi:10.1016/j.ridd.2017.07.017.

    PMID: 28844022
  16. 16

    Factors associated with sleep disturbances in children and adolescents with Angelman Syndrome.

    Leader G, Killeen C, Whelan S, et al.

    Sleep medicine 2024; (117()):9-17 doi:10.1016/j.sleep.2024.02.038.

    PMID: 38479041
  17. 17

    Neuropathology in the North American sudden unexpected death in epilepsy registry.

    Leitner DF, Faustin A, Verducci C, et al.

    Brain communications 2021; (3(3)):fcab192 doi:10.1093/braincomms/fcab192.

    PMID: 34514397
  18. 18

    Mortality in patients with epilepsy: a systematic review.

    Xu X, Sha L, Basang S, et al.

    Journal of neurology 2025; (272(4)):291 doi:10.1007/s00415-025-13002-6.

    PMID: 40133571
  19. 19

    Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.

    Lee D, Chen W, Kaku HN, et al.

    eLife 2023; (12()).

    PMID: 36594817
  20. 20

    The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial.

    Hipp JF, Bacino CA, Bird LM, et al.

    Nature medicine 2025; (31(9)):2936-2945 doi:10.1038/s41591-025-03784-7.

    PMID: 40646322
  21. 21

    [Angelman syndrome: current approach and the future of therapies].

    Sell E, Heymans J

    Medicina 2024; (84 Suppl 3()):15-20.

    PMID: 39331770

This page provides an educational overview of Angelman syndrome for caregivers. It is not a substitute for professional medical advice, diagnosis, or treatment from your child's pediatric neurologist or genetics team.

Stay up to date

Get notified when new research about Angelman syndrome is published.

No spam. Unsubscribe anytime.